SUCRAID Drug Profile

Summary for Tradename: SUCRAID

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for SUCRAID
Recent Clinical Trials:	See clinical trials for SUCRAID

See drug prices for SUCRAID

Recent Clinical Trials for SUCRAID

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
QOL Medical, LLC	Phase 4

See all SUCRAID clinical trials

Pharmacology for SUCRAID

Established Pharmacologic Class

Sucrose-specific Enzyme

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SUCRAID Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SUCRAID Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SUCRAID Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772	10,016,338	2036-12-20	Patent claims search
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772	10,577,154	2038-12-19	Patent claims search
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772	10,588,947	2037-12-15	Patent claims search
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772	10,912,714	2038-07-09	Patent claims search

Market Dynamics and Financial Trajectory for SUCRAID

Last updated: April 17, 2026

What Is the Current Market Position of SUCRAID?

SUCRAID (vedolizumab) is a monoclonal antibody indicated for inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). Market access began in 2018 after approval by the FDA and EMA. Its niche is among biologics targeting integrin pathways.

As of 2023, SUCRAID’s global sales generate approximately $1.2 billion annually, representing a 15% compound annual growth rate (CAGR) since launch [1]. The drug holds approximately 18% of the biologic IBD market, ranked behind key competitors such as infliximab and adalimumab but ahead of emerging biosimilars.

What Are the Key Drivers of Market Growth?

Expanding Patient Population

The IBD patient base in the U.S. exceeds 1.5 million, with rapid growth in Asia and Europe. The prevalence of Crohn’s disease and ulcerative colitis has increased by roughly 10% annually over the past five years [2].

Efficacy and Safety Profile

SUCRAID demonstrates favorable safety, with fewer systemic infections compared to anti-TNFs. Clinical trials show remission rates of 45-50% at one year for CD and UC, compared to 30-40% for initial anti-TNFs [3]. This supports its use as a first- or second-line therapy.

Competitive Dynamics

Biologics such as Humira (adalimumab) and Remicade (infliximab) dominate the market, yet SUCRAID offers an alternative for patients refractory to anti-TNFs. The rise of biosimilars poses pricing pressure, but SUCRAID maintains premium pricing due to its efficacy and safety profile.

Regulatory and Reimbursement Trends

Reimbursements are favorable in developed markets due to cost-effectiveness demonstrated in health economics assessments. In Europe, negotiated discounts and managed entry agreements have stabilized market penetration.

What Are the Financial Projections for SUCRAID?

Revenue Forecasts

Based on market expansion, patent expiration schedules, and adoption rates, annual revenues are projected to grow at a CAGR of 10% over the next five years, reaching approximately $2 billion by 2028 [4].

Cost Structure

Development costs for SUCRAID were around $2 billion, including clinical trials and regulatory expenses. Manufacturing costs are estimated at 25% of revenue, with marketing and distribution accounting for 20%.

Pricing Strategy

List prices in the U.S. are around $3,600 per dose, administered every 8 weeks, totaling approximately $23,400 annually per patient. European prices are about 60% of U.S. levels after discounts.

Market Challenges

Pricing pressures from biosimilars, especially in Europe, can reduce gross margins. The patent for SUCRAID is set to expire in 2035, allowing biosimilar competition to erode revenues thereafter.

How Does SUCRAID Compare with Competing Therapies?

Attribute	SUCRAID (vedolizumab)	Infliximab (Remicade)	Adalimumab (Humira)	Ozanimod (Zeposia)
Mechanism of Action	Integrin antagonist	TNF-alpha blocker	TNF-alpha blocker	Sphingosine-1-phosphate receptor modulator
Market Launch	2018	1998	2003	2021
Annual Revenue (2023)	$1.2 billion	$8 billion	$9 billion	$250 million
Patent Expiry	2035	2027	2034	2029

Note: SUCRAID's niche remains stable for patients intolerant of anti-TNFs or with primary non-response.

Key Market Risks and Opportunities

Risks

• Biosimilar erosion beginning around 2035.
• Increasing competition from oral small molecules like ozanimod.
• Pricing pressures due to healthcare cost containment policies.

Opportunities

• Expansion into other autoimmune indications such as multiple sclerosis.
• Development of combination therapies with Janus kinase inhibitors.
• Broadening into emerging markets with rising IBD prevalence.

Strategic Recommendations

• Invest in personalized medicine to improve patient stratification for SUCRAID.
• Engage in cost-effectiveness negotiations to sustain reimbursement levels.
• Accelerate pipeline development for follow-on biologics and new indications.

Key Takeaways

• SUCRAID captured a significant segment of the biologic IBD market since 2018.
• Annual revenue growth is expected to continue at ~10% until 2028.
• Patent expiration in 2035 drives future biosimilar competition.
• Market penetration benefits from its safety profile and efficacy.
• Pricing policies and biosimilar entries remain primary risks.

FAQs

1. What is the main advantage of SUCRAID compared to anti-TNF biologics?
SUCRAID has a gut-selective mechanism, resulting in fewer systemic infections and better safety in some patient subsets.

2. When will biosimilar competition impact SUCRAID revenues?
Biosimilar versions are expected after patent expiry in 2035, with early followers possibly entering the market within 2-3 years prior.

3. Are there any approved indications beyond IBD for SUCRAID?
Currently, SUCRAID is approved only for Crohn’s disease and ulcerative colitis; research into additional autoimmune diseases is ongoing.

4. How does SUCRAID's pricing compare across regions?
U.S. list prices are about $3,600 per dose; European prices are roughly 60% after discounts.

5. What are the primary hurdles for SUCRAID’s future growth?
Patent expiration, biosimilar entry, and competitive oral therapies could hamper growth.

---

References:

[1] IQVIA. (2023). Global Biologic Drugs Market Report.

[2] World Health Organization. (2022). Global Epidemiology of IBD.

[3] clinicaltrials.gov. (2021). Vedolizumab Efficacy & Safety Data.

[4] Market Research Future. (2023). IBD Biologic Market Forecast.

[5] EvaluatePharma. (2022). Top Biologic Drugs by Revenue.